It’s been a busy few weeks here at CURE® and in the oncology space as a whole, as the last two weekends had back-to-back meetings: the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium, and then their Genitourinary Cancers Symposium.  Here are some highlights from the conference, but as always, you can find all of our coverage at curetoday.com.  Gastrointestinal Cancers Symposium  Imfinzi, Avastin, TACE May ‘Set a New Standard of Care’ in Liver Cancer For patients with liver cancer whose disease is not eligible to be removed via surgery, adding Imfinz ..read more

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.  Notably, we have a clinical trial hold for a lung cancer drug, a trial that showed that a CAR-T cell therapy is cost-effective — though far from cheap — for lymphoma treatment, and a novel drug that’s showing promise for the treatment of myelofibrosis.  FDA Places Hold on Trial Evaluating TIL Therapy in NSCLC The Food and Drug Administration placed a clinical hold on the ongoing IOV-LUN-202 trial, evaluating LN-145 TIL for patients with non-small cell lun ..read more

..read more

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another cancer vaccine clinical trial that got the green light from the Food and Drug Administration.  FDA Approved Besponsa for Children With Acute Lymphoblastic Leukemia The first FDA approval of last week was one in the pediatric cancer space. The agency approved Besponsa for children who are at least 1 year old and have relapsed or refractory CD22-positive precursor acute lymphoblastic leukemia ..read more

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.  We heard from an expert about using cannabis during cancer care, took a look at a patient population that may be more prone to cardiometabolic conditions after cancer treatment and we’ll highlight a study that’s looking at preventing infection and GVHD in patients with blood cancer who underwent a stem cell transplant.  Patients Should ‘Have the Conversation’ Ab ..read more

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers.  The week’s first approval (an Onivyde regimen for metastatic pancreatic cancer) was covered in last week’s episode, but here’s a list of what has happened since that last recording.  FDA Approves Tepmetko for Metastatic NSCLC Subtype Patients with metastatic non-small cell lung cancer that has MET exon 14 skipping alterations may soon have a new treatment option, as the FDA approv ..read more

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tumor testing, and physical activity for pain reduction in cancer survivors.  FDA Approves Onivyde as First-Line Treatment of Metastatic Pancreatic Cancer On Tuesday, the Food and Drug Administration approved Onivyde plus oxaliplatin, fluorouracil and leucovorin — a regimen referred to as NALIRIFOX — for the frontline treatment of patients with metastatic adenocarcinoma. The approval was based ..read more

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered research showing that a lower dose of an anti-emetic drug could have similar efficacy — and fewer side effects — than the standard, higher dose.  NCCN Guidelines Give Framework for Childhood Neuroblastoma Treatment The National Comprehensive Cancer Network recently published guidelines for the treatment of pediatric patients with neuroblastoma. This resource is geared toward mitigating unnecessary ..read more

Last week, we saw some research regarding how a popular tool used to plan breast cancer treatment may be misguiding therapy for Black women, as well as an update on when we can expect to see a new cancer vaccine be readily available for patients.  And on the FDA front, we’ll discuss a priority review for Enhertu for patients with HER2-positive solid cancers, as well as a fast track designation for a new drug duo in the lung cancer space.  Cancer Vaccine Likely ‘Several Years’ Away From Wide Availability ELI-002 is a vaccine being investigated for the treatment of patients with K ..read more

Last week, we saw some big headlines in the oncology space, from Dexter Scott King’s death from prostate cancer and MLB Hall-of-Famer Ryne Sandberg announcing that he was diagnosed with the disease.  The FDA also requested a label update for CAR-T cell therapies that would warn patients and providers about secondary malignancies that have been reported from the treatment. Also, we took a look at laughter therapy, and how it could help patients and caregivers.  We’ve also been busy covering two conferences — ASCO’s Gastrointestinal Cancers Symposium, as well as their Genitourinary C ..read more